Clinical Trials of Thermosensitive Nanomaterials: An Overview

Area of Science:

• Nanotechnology and Materials Science
• Biomedical Engineering
• Clinical Medicine

Background:

• Increasing demand for advanced healthcare solutions necessitates innovative disease detection and treatment systems.
• Stimuli-responsive nanomaterials offer potential for significant improvements in healthcare.
• Thermosensitive nanomaterials are a key area of research for medical applications.

Purpose of the Study:

• To review clinical trials of thermosensitive nanomaterials and hybrid nanomaterials responding to other stimuli.
• To discuss the current and potential applications of these nanomaterials in disease diagnosis and treatment.
• To highlight the discrepancy between research publications and clinical implementation of thermosensitive nanomaterials.

Main Methods:

• Comprehensive review of existing clinical trials involving thermosensitive and hybrid nanomaterials.
• Analysis of the specific applications and stimuli utilized in these trials.
• Evaluation of the current clinical utility and future prospects of thermosensitive nanomaterials.

Main Results:

• No current diagnostic clinical trials leverage thermosensitive properties; Ferumoxytol is primarily used as an imaging enhancer.
• Thermosensitive nanomaterials are predominantly explored for disease treatment, especially in antitumor drug delivery (e.g., ThermoDox® with doxorubicin).
• A notable gap exists between the volume of research papers and the number of clinical trials, suggesting the field's relative novelty.

Conclusions:

• Thermosensitive nanomaterials show significant promise for enhancing disease treatment, particularly in targeted drug delivery.
• Further clinical validation is required to bridge the gap between research and clinical application.
• Future clinical trials are expected to increase, potentially improving patient quality of life and life expectancy.